Table 3.
Ten independent cross-cancer signals in 5p15.33 region identified in the joint analysis of COJO-ASSET
| No. of iteration | SNP with top ASSET p value | ASSET p valuea | Significant cancer subset, identified by ASSETb | GWAS p valuesc |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ER-neg BrCa | Colorectal | Glioma | Lung | Melanoma | Ovarian | Pancreatic | Prostate | ||||
| Initiation | rs10069690 (5:1279790:C:T) | 4.05E−126 | set 1: ER-neg BrCa, glioma; set 2: pancreatic, prostate | 1.34E−35∗ | 1.13E−01 | 2.32E−66∗ | 9.39E−01 | 9.08E−01 | 1.74E−08∗ | 3.29E−03 | 1.44E−45∗ |
| 1 | rs465498 (5:1325803:A:G) | 1.75E−59 | set 1: melanoma, pancreatic; set 2: lung | 1.61E−02 | 3.89E−02 | 6.85E−05 | 2.68E−32∗ | 2.08E−17∗ | 1.49E−01 | 7.45E−17∗ | 9.15E−05 |
| 2 | rs2853677 (5:1287194:G:A) | 3.24E−39 | set 1: ER-neg BrCa, colorectal, lung; set 2: glioma, melanoma, ovarian, pancreatic, prostate | 4.94E−05 | 3.65E−10∗ | 1.08E−28∗ | 2.66E−18∗ | 1.12E−02 | 1.49E−06 | 2.87E−08∗ | 1.53E−02 |
| 3 | rs11414507 (5:1291331:A:AC) | 1.29E−19 | set 1: ER-neg BrCa; set 2: prostate | 1.34E−16∗ | NA | NA | NA | NA | 1.63E−04 | 8.18E−01 | 1.61E−45∗ |
| 4 | rs35033501 (5:1253918:C:T) | 9.18E−15 | set 1: lung, melanoma, prostate; set 2: ER-neg BrCa, pancreatic | 9.90E−05 | 8.55E−03 | 1.24E−02 | 3.84E−01 | 3.66E−02 | 5.55E−01 | 4.48E−05 | 2.37E−15∗ |
| 5 | rs7705526 (5:1285974:C:A) | 1.42E−11 | set 1: glioma, lung, melanoma; set 2: ER-neg BrCa, colorectal, pancreatic, prostate | 1.37E−04 | 3.17E−04 | 5.01E−61∗ | 1.01E−18∗ | 3.24E−03 | 1.34E−09∗ | 2.15E−03 | 2.78E−14∗ |
| 6 | rs192723047 (5:1273183:A:G) | 1.63E−11 | set 1: prostate; set 2: ER-neg BrCa | 4.37E−17∗ | NA | NA | NA | NA | 1.21E−02 | 8.96E−02 | 5.40E−24∗ |
| 7 | rs35226131 (5:1295373:C:T) | 2.32E−09 | set 1: pancreatic; set2: colorectal, glioma, prostate | 8.83E−02 | 5.17E−07 | 8.66E−01 | NA | NA | 3.63E−01 | 4.30E−08∗ | 3.20E−06 |
| 8 | rs35334674 (5:1292299:G:A) | 1.24E−08 | set 1: ER-neg BrCa, pancreatic; set 2: colorectal, glioma, lung, prostate | 3.36E−02 | 4.40E−07 | 4.07E−02 | 2.15E−02 | NA | 5.93E−01 | 1.43E−02 | 3.23E−02 |
| 9 | rs3888705 (5:1298645:G:A) | 2.65E−08 | set 1: ER-neg BrCa, colorectal, ovarian; set 2: pancreatic, prostate | 1.78E−02 | 1.04E−03 | 9.32E−07 | 3.62E−03 | NA | 2.75E−03 | 7.13E−01 | 1.94E−03 |
| 10 | rs148487301 (5:1318797:T:C) | 8.70E−06 | not reached genome-wide significance, iteration stopped | ||||||||
∗Genome-wide significance with p value < 5 × 10−8. BrCa, breast cancer; NA, the SNP was not included in the GWAS results of corresponding cancer..
a
p values from the ASSET meta-analysis allowing opposite direction of the effect (two-sided analysis).
b
Cancer subsets included in the two-sided ASSET meta-analysis with best p value. Set 1/2 represents the selected cancer types with positive/negative association with the SNP.
c
p values from the original GWAS results of eight cancers.